Is a targeted biopsy-only approach for prostate cancer diagnosis ready for the prime time?

Nature Reviews Urology, Published online: 04 December 2020; doi:10.1038/s41585-020-00412-6The PRECISION trial demonstrated the ability of using multiparametric MRI to improve the diagnosis of clinically significant prostate cancer whilst reducing over-diagnosis of clinically insignificant cancer compared with systematic biopsy. Concerns remained about patients who were not biopsied owing to negative scans. A new study applies the PRECISION strategy to a contemporary cohort to answer these concerns.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research